Avita Medical Ltd (RCEL)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $478.22M
Last updated: Nov 17, 2026 at 4:15 PM ET
Avita Medical Ltd (RCEL) Statistics
Avita Medical (RCEL) has a market cap of $478.22M and an enterprise value of $517.85M. Its share count is up 8.71% from a year earlier. It kept -42.65% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 8.29% above the market cap, as debt exceeds cash.
| Market Cap | $478.22M |
|---|---|
| Enterprise Value | $517.85M |
| Latest price (Nov 17, 2026) | $15.77 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 5.7x. Its year-end P/S ranged from 1.3x to 10.1x from 2021 to 2025.
| P/S Ratio | 5.7x |
|---|---|
| Forward P/S | 3.5x |
Price Statistics
The stock is up 320.53% over 52 weeks and trades 16.04% above its 50-day average.
| Beta (1Y) | 1.57 |
|---|---|
| 52-Week Change | +320.53% |
| 1-Month Change | +20.02% |
| 3-Month Change | +52.51% |
| 6-Month Change | +275.92% |
| 5-Year Change | -4.98% |
| Total Return (1Y) | +320.53% |
| Total Return (3Y CAGR) | +7.77% |
| Total Return (5Y CAGR) | +0.48% |
| Return vs SPY (1Y) | +287.68% |
| Max Drawdown (1Y) | -32.65% |
| Max Drawdown (3Y) | -82.14% |
| Sharpe Ratio (1Y) | 1.65 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $13.59 |
| 200-Day Average | $7.27 |
| 52-Week Range | $3.22 to $18.43 |
| RSI (14 Days) | 54.0 |
| Average Volume (20 Days) | 612.94K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.20x current liabilities.
| Current Ratio | 1.20x |
|---|---|
| Quick Ratio | 0.99x |
| Interest Coverage | -5.42x |
Returns and Efficiency
Return on invested capital is -159.34% over the last 12 months, against a 5-year average of -71.73%.
| Return on Assets (ROA) | -77.18% |
|---|---|
| Return on Invested Capital (ROIC) | -159.34% |
| Return on Capital Employed (ROCE) | -128.08% |
| ROIC (5Y Average) | -71.73% |
| Asset Turnover | 1.53x |
| Inventory Turnover | 2.96x |
| Receivables Turnover | 8.38x |
| Cash Conversion Cycle | 29 days |
Scores
RCEL has an Altman Z-Score of -9.42, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.42 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $84.68M over the last 12 months is up 16.97% from the 12 months before.
| Revenue | $84.68M |
|---|---|
| Revenue Growth (YoY) | +16.97% |
| Gross Profit | $69.75M |
| Operating Income | -$28.69M |
| Pretax Income | -$36.05M |
| Net Income | -$36.12M |
| EBITDA | -$28.11M |
| EBIT | -$30.43M |
| Reported EPS (TTM) | -$1.47 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $10.50M |
|---|---|
| Total Debt | $50.13M |
| Net Debt | $39.63M |
| Net Debt Per Share | $1.28 |
| Working Capital | $4.64M |
| Shareholder Equity | -$31.04M |
| Tangible Book Value | -$36.59M |
| Total Assets | $46.79M |
| Total Liabilities | $77.83M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $277.00K of capital spending, operating cash flow left -$19.99M of free cash flow.
| Operating Cash Flow | -$19.72M |
|---|---|
| Capital Expenditures | $277.00K |
| Free Cash Flow | -$19.99M |
| FCF Per Share | -$0.64 |
| Depreciation and Amortization | $2.73M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -33.88%.
| Gross Margin | 82.36% |
|---|---|
| Operating Margin | -33.88% |
| Pretax Margin | -42.57% |
| Net Margin | -42.65% |
| EBITDA Margin | -33.20% |
| EBIT Margin | -35.93% |
| FCF Margin | -23.61% |
Dividends and Yields
RCEL does not pay a dividend. Its free cash flow yield is -4.11%.
| FCF Yield | -4.11% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-5 reverse split on Jun 30, 2020.
| Last Split Date | Jun 30, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:5 |
Peer Position
Against 12 similar companies, RCEL has the 3rd highest P/S.
P/S RatioPeer median 1.8x
ROICPeer median -0.17%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.21%
| P/S Ratio | 5.7x vs 1.8x median |
|---|---|
| ROIC | -159.34% vs -0.17% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +16.97% vs +14.21% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RCEL
What is RCEL's market cap?
Avita Medical has a market cap of $478.22M. Its enterprise value, which adds debt and subtracts cash, is $517.85M.
How many shares of RCEL are outstanding?
Avita Medical has 30.87M shares outstanding. The count is up 8.71% from a year earlier.
Does RCEL pay a dividend?
No. Avita Medical does not pay a dividend.
How much debt does RCEL have?
Avita Medical has $50.13M of total debt and $10.50M of cash and equivalents, a net debt position of $39.63M.
RCEL pages: Overview, Charting, Earnings, Forecast, Statistics, Competitors